Nektar's Q2 Loss Widens Amid Revenue Dip, Raises $85M in Offerings

TL;DR

**NKTR is burning cash and diluting shareholders to stay afloat, but the capital raise buys them time for Rezpegaldesleukin.**

AI Summary

NEKTAR THERAPEUTICS reported a net loss of $59.5 million for the quarter ended June 30, 2025, a significant increase from the $48.3 million net loss in the prior-year quarter. Total revenue for the quarter decreased to $10.2 million from $12.5 million, primarily due to a reduction in product revenue to $1.2 million from $2.1 million. Research and development expenses saw a slight decrease to $45.8 million from $46.2 million, while general and administrative expenses increased to $20.1 million from $14.6 million. The company completed an underwritten public offering on July 2, 2025, issuing 100,000,000 shares of common stock at $0.75 per share, generating gross proceeds of $75.0 million. This offering, along with a private placement of 13,333,333 shares to TCG Crossover Fund II, L.P. for $10.0 million, aims to bolster the company's cash position. The company is also advancing its Rezpegaldesleukin program, with ongoing clinical trials, and is exploring strategic alternatives for its NKTR-255 program.

Why It Matters

NEKTAR's widening net loss and declining revenue signal ongoing operational challenges, putting pressure on its drug development pipeline. The recent capital raises, totaling $85 million, are critical for funding its Rezpegaldesleukin program and other R&D efforts, but also dilute existing shareholders. In a competitive biopharmaceutical landscape, the ability to efficiently advance clinical assets like Rezpegaldesleukin is paramount for NEKTAR to regain investor confidence and secure future partnerships. The company's strategic decisions regarding NKTR-255 will also impact its long-term competitive positioning and market value.

Risk Assessment

Risk Level: high — The company reported a net loss of $59.5 million for the quarter, an increase from $48.3 million in the prior year, indicating significant cash burn. Revenue decreased to $10.2 million from $12.5 million, highlighting a struggle to generate income. The reliance on recent equity offerings, including 100,000,000 shares at $0.75 per share, to fund operations demonstrates a high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider the significant dilution from the recent equity offerings. Monitor the progress of the Rezpegaldesleukin program closely, as its success is crucial for NEKTAR's long-term viability, and evaluate the company's cash runway against its burn rate.

Financial Highlights

debt To Equity

N/A

revenue

$10.2M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$59.5M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-18.4%

Revenue Breakdown

Key Numbers

• $59.5M — Net Loss (Increased from $48.3M in Q2 2024, indicating worsening profitability.)
• $10.2M — Total Revenue (Decreased from $12.5M in Q2 2024, showing a decline in sales.)
• $1.2M — Product Revenue (Down from $2.1M in Q2 2024, reflecting reduced product sales.)
• $45.8M — R&D Expenses (Slightly decreased from $46.2M in Q2 2024, but still a major cost center.)
• $20.1M — G&A Expenses (Increased from $14.6M in Q2 2024, contributing to higher operating costs.)
• $75.0M — Public Offering Gross Proceeds (Generated from 100,000,000 shares at $0.75, providing critical liquidity.)
• $10.0M — Private Placement Proceeds (From TCG Crossover Fund II, L.P. for 13,333,333 shares, further boosting cash.)
• 100,000,000 — Shares Issued (In the underwritten public offering, leading to significant shareholder dilution.)

Key Players & Entities

• NEKTAR THERAPEUTICS (company) — filer of the 10-Q
• TCG Crossover Fund II, L.P. (company) — investor in private placement
• Rezpegaldesleukin (drug) — key clinical program
• NKTR-255 (drug) — program exploring strategic alternatives
• Eli Lilly and Company (company) — partner mentioned in prior agreements
• Bristol-Myers Squibb Company (company) — partner mentioned in prior agreements
• Gannet BioChem (company) — entity related to a disposal group
• $59.5 million (dollar_amount) — net loss for Q2 2025
• $10.2 million (dollar_amount) — total revenue for Q2 2025
• $75.0 million (dollar_amount) — gross proceeds from underwritten public offering

FAQ

Risk Factors

• Continued Net Losses and Cash Burn [high — financial]: The company reported a net loss of $59.5 million for Q2 2025, an increase from $48.3 million in the prior year. This persistent net loss, coupled with declining revenues, highlights ongoing financial challenges and the need for capital infusions.
• Dependence on Future Financing [high — financial]: The company recently completed a public offering and private placement to raise $85 million in gross proceeds. This indicates a reliance on external financing to sustain operations, which carries risks related to market conditions and investor confidence.
• Clinical Trial and Development Risks [high — operational]: Nektar is advancing its Rezpegaldesleukin program, which involves ongoing clinical trials. The success of these trials is critical for future revenue generation, and any setbacks or delays pose a significant risk to the company's pipeline and financial outlook.
• Strategic Alternatives for NKTR-255 [medium — operational]: The company is exploring strategic alternatives for its NKTR-255 program. This uncertainty could impact resource allocation and future development plans, with outcomes dependent on market interest and potential divestiture terms.
• Increasing General and Administrative Expenses [medium — financial]: G&A expenses increased to $20.1 million from $14.6 million in the prior-year quarter. This rise in overhead costs, while R&D expenses remained relatively stable, contributes to the widening net loss and impacts overall operational efficiency.
• Shareholder Dilution [medium — financial]: The underwritten public offering issued 100,000,000 shares of common stock. Such a large issuance can lead to significant dilution for existing shareholders, potentially impacting the value of their holdings.

Industry Context

Nektar Therapeutics operates in the highly competitive biopharmaceutical industry, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. The industry is driven by innovation in drug discovery and clinical efficacy, with companies often relying on strategic partnerships and capital markets to fund their operations and advance pipelines.

Regulatory Implications

As a biopharmaceutical company, Nektar is subject to rigorous regulatory scrutiny from bodies like the FDA. Approval processes for new drugs are lengthy and costly, and any adverse findings or delays in clinical trials can have substantial financial and operational consequences. Compliance with evolving healthcare regulations is also a critical factor.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate the progress and success of the Rezpegaldesleukin clinical trials.
3. Assess the outcome of the strategic review for the NKTR-255 program.
4. Consider the impact of shareholder dilution from recent offerings.

Key Dates

• 2025-06-30: Quarter End Date — Reporting period for the 10-Q filing, reflecting the company's financial performance and position.
• 2025-07-02: Underwritten Public Offering Completion — Raised $75.0 million in gross proceeds, providing crucial liquidity but also causing shareholder dilution.
• 2025-07-01: Private Placement to TCG Crossover Fund II, L.P. — Raised $10.0 million, further strengthening the company's cash reserves.
• 2025-08-08: 10-Q Filing Date — Official release of the quarterly financial report to the public and regulatory bodies.

Glossary

Underwritten Public Offering

A type of securities offering where an underwriter (typically an investment bank) buys the securities from the issuer and resells them to the public. (Nektar Therapeutics used this to raise $75.0 million, indicating a need for capital and impacting share count.)

Private Placement

A direct sale of securities to a select group of investors, rather than through a public offering. (Nektar Therapeutics raised $10.0 million through this method, supplementing its public offering.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Nektar reported a net loss of $59.5 million for the quarter, highlighting its unprofitability.)

Product Revenue

Revenue generated from the sale of the company's manufactured products. (A key component of Nektar's total revenue, which saw a significant decline in the quarter.)

Research and Development Expenses (R&D)

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A major expense for Nektar, crucial for its drug development pipeline, though slightly decreased.)

General and Administrative Expenses (G&A)

Costs associated with the overall management and operation of a business, not directly tied to production or sales. (These expenses increased significantly, contributing to the company's higher net loss.)

Shareholder Dilution

The reduction in the ownership percentage of a stock that occurs when a company issues new shares. (A direct consequence of the large underwritten public offering, impacting existing shareholders.)

Strategic Alternatives

Exploring various options for a business or a specific asset, which could include mergers, acquisitions, divestitures, or partnerships. (Nektar is considering these for its NKTR-255 program, indicating a potential shift in its development strategy.)

Year-Over-Year Comparison

Compared to the prior-year quarter, Nektar Therapeutics experienced a notable decline in total revenue, falling from $12.5 million to $10.2 million, with product revenue seeing a sharper decrease from $2.1 million to $1.2 million. While R&D expenses remained relatively stable, a significant increase in G&A expenses from $14.6 million to $20.1 million contributed to a widening net loss, which grew from $48.3 million to $59.5 million. The company has also undertaken substantial financing activities post-quarter end to bolster its cash position.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR NASDAQ Capital Marke

Filing Documents

• nktr-20250630.htm (10-Q) — 2613KB
• nktr-ex31_1.htm (EX-31.1) — 14KB
• nktr-ex31_2.htm (EX-31.2) — 15KB
• nktr-ex32_1.htm (EX-32.1) — 11KB
• 0000950170-25-105275.txt ( ) — 9786KB
• nktr-20250630.xsd (EX-101.SCH) — 1361KB
• nktr-20250630_htm.xml (XML) — 1755KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements — Unaudited: 6 Condensed Consolidated Balance Sheets — June 30, 2025 and December 31, 2024 6 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 8 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and six months ended June 30, 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 38

: OTHER INFORMATION

PART II: OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 64 Item 3. Defaults Upon Senior Securities 64 Item 4. Mine Safety Disclosures 64 Item 5. Other Information 64 Item 6. Exhibits 65

Signatures

Signatures 67 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of any collaboration arrangements, commercialization activities and product sales levels and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as "believe," "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "continue," or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reaso

: FINANCI AL INFORMATION

PART I: FINANCI AL INFORMATION

Condensed Consolidated Financial Statements—Unaudited

Item 1. Condensed Consolidated Financial Statements—Unaudited: NEKTAR THERAPEUTICS CONDENSED CONSOLID ATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) June 30, 2025 December 31, 2024 (1) ASSETS Current assets: Cash and cash equivalents $ 42,988 $ 44,252 Short-term investments 132,915 210,974 Other current assets 10,663 6,066 Total current assets 186,566 261,292 Long-term investments — 13,869 Property and equipment, net 2,988 3,411 Operating lease right-of-use assets 7,585 8,413 Equity method investment in Gannet BioChem 5,371 12,218 Other assets 5,024 4,647 Total assets $ 207,534 $ 303,850 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable (including $ 693 and $ 0 as of June 30, 2025 and December 31, 2024, respectively, to a related party) $ 14,281 $ 11,560 Accrued expenses (including $ 4,613 and $ 3,403 as of June 30, 2025 and December 31, 2024, respectively, to a related party) 35,099 29,972 Operating lease liabilities, current portion 22,011 19,868 Total current liabilities 71,391 61,400 Operating lease liabilities, less current portion 74,145 82,696 Liabilities related to the sales of future royalties, net 80,573 91,776 Other long-term liabilities 5,636 7,241 Total liabilities 231,745 243,113 Commitments and contingencies Stockholders' equity (deficit): Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at June 30, 2025 or December 31, 2024, respectively — — Common stock, $ 0.0001 par value; 390,000,000 shares and 300,000,000 shares authorized at June 30, 2025 and December 31, 2024; 13,009,559 shares and 12,937,308 shares issued at June 30, 2025 and December 31, 2024, respectively; 12,457,252 shares and 12,385,001 shares outstanding at June 30, 2025 and December 31, 2024, respectively; 1 1 Ca

View Full Filing

View this 10-Q filing on SEC EDGAR